Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dual roles of TLR7 in the lung cancer microenvironment.

Literature DB >> 25949912

Dual roles of TLR7 in the lung cancer microenvironment.

Marion Dajon¹, Kristina Iribarren¹, Isabelle Cremer¹.

Abstract

Toll-like receptor 7 (TLR7) agonists are under investigation for their ability to enhance antitumor immune responses. However, these agonists can also stimulate TLR7-expressing tumor cells. High TLR7 expression in the primary tumor confers poor clinical outcome and resistance to chemotherapy in lung cancer patients. This protumorigenic effect of TLR7 has been validated in murine models of lung carcinoma.

Entities: Disease Gene Species

Keywords: MDSC; TLR7; chemoresistance; lung cancer

Year: 2015 PMID： 25949912 PMCID： PMC4404797 DOI： 10.4161/2162402X.2014.991615

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

10 in total

1. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.

Authors: Erina Koga-Yamakawa; Simon J Dovedi; Masashi Murata; Hiroyuki Matsui; Andrew J Leishman; John Bell; Douglas Ferguson; Simon P Heaton; Toshihiro Oki; Hideyuki Tomizawa; Ash Bahl; Haruo Takaku; Robert W Wilkinson; Hideyuki Harada
Journal: Int J Cancer Date: 2012-07-11 Impact factor: 7.396

2. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans.

Authors: Atsuo Ochi; Christopher S Graffeo; Constantinos P Zambirinis; Adeel Rehman; Michael Hackman; Nina Fallon; Rocky M Barilla; Justin R Henning; Mohsin Jamal; Raghavendra Rao; Stephanie Greco; Michael Deutsch; Marco V Medina-Zea; Usama Bin Saeed; Melvin O Ego-Osuala; Cristina Hajdu; George Miller
Journal: J Clin Invest Date: 2012-11 Impact factor: 14.808

3. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance.

Authors: Julien Cherfils-Vicini; Sophia Platonova; Mélanie Gillard; Ludivine Laurans; Pierre Validire; Rafaele Caliandro; Pierre Magdeleinat; Fathia Mami-Chouaib; Marie-Caroline Dieu-Nosjean; Wolf-Herman Fridman; Diane Damotte; Catherine Sautès-Fridman; Isabelle Cremer
Journal: J Clin Invest Date: 2010-03-08 Impact factor: 14.808

4. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes.

Authors: Carlos Serra-Guillén; Eduardo Nagore; Luis Hueso; Victor Traves; Francesc Messeguer; Onofre Sanmartín; Beatriz Llombart; Celia Requena; Rafael Botella-Estrada; Carlos Guillén
Journal: J Am Acad Dermatol Date: 2012-01-09 Impact factor: 11.527

5. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.

Authors: Daqing Wang; Melissa Precopio; Tao Lan; Dong Yu; Jimmy X Tang; Ekambar R Kandimalla; Sudhir Agrawal
Journal: Mol Cancer Ther Date: 2010-06-01 Impact factor: 6.261

6. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.

Authors: Michael G Kelly; Ayesha B Alvero; Rui Chen; Dan-Arin Silasi; Vikki M Abrahams; Serena Chan; Irene Visintin; Thomas Rutherford; Gil Mor
Journal: Cancer Res Date: 2006-04-01 Impact factor: 12.701

7. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma.

Authors: Fatma E Mohamed; Rajai M Al-Jehani; Shane S Minogue; Fausto Andreola; Alison Winstanley; Steven W M Olde Damink; Abeba Habtesion; Massimo Malagó; Nathan Davies; Tu Vinh Luong; Amar P Dhillon; Rajeshwar P Mookerjee; Dipok K Dhar; Rajiv Jalan
Journal: Liver Int Date: 2014-07-30 Impact factor: 5.828

8. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment.

Authors: Isabelle Le Mercier; Dominique Poujol; Amélien Sanlaville; Vanja Sisirak; Michael Gobert; Isabelle Durand; Bertrand Dubois; Isabelle Treilleux; Jacqueline Marvel; Jaromir Vlach; Jean-Yves Blay; Nathalie Bendriss-Vermare; Christophe Caux; Isabelle Puisieux; Nadège Goutagny
Journal: Cancer Res Date: 2013-05-30 Impact factor: 12.701

9. TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer.

Authors: Saradiya Chatterjee; Lucile Crozet; Diane Damotte; Kristina Iribarren; Catherine Schramm; Marco Alifano; Audrey Lupo; Julien Cherfils-Vicini; Jeremy Goc; Sandrine Katsahian; Mohammad Younes; Marie Caroline Dieu-Nosjean; Wolf Herman Fridman; Catherine Sautès-Fridman; Isabelle Cremer
Journal: Cancer Res Date: 2014-07-29 Impact factor: 12.701

10. Immunomodulation by imiquimod in patients with high-risk primary melanoma.

Authors: Rupa Narayan; Hong Nguyen; Jason J Bentow; Lauren Moy; Diana K Lee; Stephanie Greger; Jacquelyn Haskell; Veena Vanchinathan; Pei-Lin Chang; Shanli Tsui; Tamiko Konishi; Begonya Comin-Anduix; Christine Dauphine; Hernan I Vargas; James S Economou; Antoni Ribas; Kevin W Bruhn; Noah Craft
Journal: J Invest Dermatol Date: 2011-08-18 Impact factor: 8.551

10 in total

13 in total

1. Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer.

Authors: Yinghui Xu; Hongliang Liu; Shun Liu; Yanru Wang; Jichun Xie; Thomas E Stinchcombe; Li Su; Ruyang Zhang; David C Christiani; Wei Li; Qingyi Wei
Journal: Int J Cancer Date: 2018-09-21 Impact factor: 7.396

2. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist.

Authors: Tadashi Hosoya; Fumi Sato-Kaneko; Alast Ahmadi; Shiyin Yao; Fitzgerald Lao; Kazutaka Kitaura; Takaji Matsutani; Dennis A Carson; Tomoko Hayashi
Journal: Proc Natl Acad Sci U S A Date: 2018-07-02 Impact factor: 11.205

3. WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma.

Authors: Qihang Yuan; Qi Zhou; Jie Ren; Guan Wang; Chunlai Yin; Dong Shang; Shilin Xia
Journal: Cancer Med Date: 2021-05-12 Impact factor: 4.452

4. The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer.

Authors: Jianchun Zhou; Yu Xu; Guansong Wang; Tonghua Mei; Hao Yang; Yuliang Liu
Journal: Int J Oncol Date: 2022-05-13 Impact factor: 5.884

5. Pellino-1 confers chemoresistance in lung cancer cells by upregulating cIAP2 through Lys63-mediated polyubiquitination.

Authors: Yoon Kyung Jeon; Chung Kwon Kim; Jaemoon Koh; Doo Hyun Chung; Geun-Hyoung Ha
Journal: Oncotarget Date: 2016-07-05

6. Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells.

Authors: Marion Dajon; Kristina Iribarren; Florent Petitprez; Solenne Marmier; Audrey Lupo; Mélanie Gillard; Hanane Ouakrim; Navas Victor; Di Bartolo Vincenzo; Pierre Emmanuel Joubert; Oliver Kepp; Guido Kroemer; Marco Alifano; Diane Damotte; Isabelle Cremer
Journal: Oncoimmunology Date: 2018-10-11 Impact factor: 8.110